European Union - English - EMA (European Medicines Agency)

serono europe limited - efalizumab - psoriasis - immunosuppressants - treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and puva (see section 5.1 - clinical efficacy).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck serono ltd - lutropin alfa - powder and solvent for solution for injection - 75unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck serono ltd - follitropin alfa; lutropin alfa - powder and solvent for solution for injection - 150unit ; 75unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck serono ltd - choriogonadotropin alfa - solution for injection - 500microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck serono ltd - cetrorelix acetate - powder and solvent for solution for injection - 250microgram

Ireland - English - HPRA (Health Products Regulatory Authority)

merck serono (ireland) limited - metformin hydrochloride - film-coated tablet - 500 milligram(s) - biguanides; metformin

Ireland - English - HPRA (Health Products Regulatory Authority)

merck serono (ireland) limited - metformin hydrochloride - film-coated tablet - 850 milligram(s) - biguanides; metformin

Ireland - English - HPRA (Health Products Regulatory Authority)

merck serono (ireland) limited - metformin hydrochloride - film-coated tablet - 1000 milligram(s) - biguanides; metformin

Ireland - English - HPRA (Health Products Regulatory Authority)

ares-serono (europe) limited - interferon beta - 1a - solution for injection - 22 mcg mcg/dose

European Union - English - EMA (European Medicines Agency)

merck europe b.v.  - lutropin alfa - ovulation induction; infertility, female - sex hormones and modulators of the genital system, - luveris in association with a follicle-stimulating-hormone (fsh) preparation is recommended for the stimulation of follicular development in women with severe luteinising-hormone (lh) and fsh deficiency. in clinical trials, these patients were defined by an endogenous serum lh level